Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferior

Non-inferiority was reported between the 2 and 3 drug regimen (n= 1441) for virological treatment efficacy (adjusted treatment difference −1.7%; 95% CI −4.4 to 1.1, using a non-inferiority margin of −10%), and viral suppression was observed in at least 90% of the study population

The study also reported fewer treatment-related adverse events with the two- versus three-drug regimen, although this benefit was mostly due to fewer mild nausea events, considered a transient side-effect.